Theratechnologies develops therapies for unmet medical needs in commercially attractive specialty markets.

Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers novel therapeutic products for development and commercialization. These products target unmet medical needs in commercially attractive specialty markets.

In the clinic

Tesamorelin Phase 3 Results

Find out more on the study

 

 

Products

Our lead product: tesamorelin

Antiretrovirals have increased the life expectancy of HIV patients. Despite the benefits of these therapies, they are associated with side-effects such as lipodystrophy. We are currently studying the effects of tesamorelin (TH9507) on excessive visceral fat, an important characteristic of HIV-associated lipodystrophy. More...

Investors

See our investor kit:

2007Annual Report

Quarterly report

First scientific symposium, sponsored by Theratechnologies, at the 11th European AIDS Conference.

Access the symposium's webcast


 

News

  • August 4, 2008 - Theratechnologies Reports on Positive Body Image Parameters at the International AIDS Conference More...
  • July 31, 2008 - Theratechnologies Presents at Both BMO and Canaccord Adams Conferences and Comments on Strategic Review More...
  • July 9, 2008 - Theratechnologies Announces Financial Results and Highlights for the Second Quarter 2008 More...

Events

  • August 14, 2008 - 28th Annual Canaccord Adams Global Growth Conference More...
  • August 4, 2008 - BMO Capital Markets Focus on Healthcare Conference More...
  • From May 6 to 8, 2008 - BioFinance 2008 More...